TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
83 hedge funds and large institutions have $72.2M invested in TCR2 Therapeutics Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 37 reducing their positions, and 23 closing their positions.
221% more call options, than puts
Call options by funds: $1.94M | Put options by funds: $605K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $74.8M → $72.2M (-$2.61M)
12% less funds holding
Funds holding: 94 → 83 (-11)
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
70% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.66M |
| 2 |
NM
Newtyn Management
New York
|
+$1.71M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.58M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$749K |
| 5 |
Millennium Management
New York
|
+$540K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.69M |
| 2 |
Renaissance Technologies
New York
|
-$1.71M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.02M |
| 4 |
Two Sigma Investments
New York
|
-$1.01M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$795K |
TCRR Hedge Fund Activity: Q2 2022 in Review
83 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2022, worth a combined $72.2M — down 3.5% from $74.8M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TCRR and 14 opened new positions — a net loss of 9 holders — while 37 trimmed existing stakes and 11 added.
The largest buyer was K2 Principal Fund, opening a new position worth an estimated $2.66M. The largest seller was BlackRock, cutting an estimated $3.69M.
- 83 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2022, down from 94 in Q1 2022.
- Funds reported $72.2M of TCR2 Therapeutics Inc. Common Stock stock for Q2 2022, down 3.5% quarter-over-quarter.
- 14 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2022 and 23 closed out, a net change of -9 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q2 2022 was K2 Principal Fund, an estimated $2.66M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $3.69M sold.
Based on aggregated 13F filings for Q2 2022.